EL
Enliven Therapeutics, Inc.
ELVN · NASDAQ
$56.23 -1.88% (-$1.08)
1M -2.92%
Market Cap $4.02B
P/E Ratio -
Div. Yield -
ROE 18.55%
Bulios Fair Price
$43.82
22.1% downside
Current Price
$56.23
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ELVN is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
44 /100
Fair P/B 4.49x
EV/EBITDA N/A
P/S N/A
Growth
-
N/A Rev. growth N/A
FCF growth N/A
Book val. growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
0 /100
Poor ROE 18.55%
ROA 11.64%
Asset turnover 0.00x
Debt
100 /100
Low Current ratio 64.07x
Debt/Equity 0.00x
Net debt/EBITDA N/A
Stability
29 /100
Unstable EPS volatility 35.88%
Profitable years 0
Beta 0.24x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ELVN
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Richard A. Fair
Employees
67
Headquarters
Boulder
Upcoming events
11 NOV
Earnings
Upcoming earnings report